From the Winship Cancer Institute, Emory University, Atlanta, GA; and Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL.
Cancer J. 2019 Mar/Apr;25(2):106-115. doi: 10.1097/PPO.0000000000000369.
It has long been recognized that combining radiotherapy with cytotoxic drugs such as cisplatin can improve efficacy. However, while concurrent chemoradiotherapy improves patient outcomes, it comes at costs of increased toxicity. A tremendous opportunity remains to investigate drug combinations in the clinical setting that might increase the benefits of radiation without additional toxicity. This chapter highlights opportunities to apply repurposing of drugs along with a mechanistic understanding of radiation effects on cancer and normal tissue to discover new therapy-modifying drugs and help rapidly translate them to the clinic. We survey candidate radiosensitizers that alter DNA repair, decrease hypoxia, block tumor survival signaling, modify tumor metabolism, block growth factor signaling, slow tumor invasiveness, impair angiogenesis, or stimulate antitumor immunity. Promising agents include widely used drugs such as aspirin, metformin, and statins, offering the potential to improve outcomes, decrease radiation doses, and lower costs. Many other candidate drugs are also discussed.
长期以来,人们已经认识到将放射治疗与顺铂等细胞毒性药物联合使用可以提高疗效。然而,虽然同步放化疗改善了患者的预后,但也带来了毒性增加的代价。在临床环境中,仍然有很大的机会研究药物联合应用,这些药物可能在不增加毒性的情况下增加放射治疗的益处。这一章强调了机会,即应用药物的重新定位,以及对放射对癌症和正常组织影响的机制理解,以发现新的治疗修饰药物,并帮助它们快速转化为临床应用。我们调查了候选放射增敏剂,这些药物可以改变 DNA 修复、减少缺氧、阻断肿瘤存活信号、改变肿瘤代谢、阻断生长因子信号、减缓肿瘤侵袭性、损害血管生成或刺激抗肿瘤免疫。有前途的药物包括阿司匹林、二甲双胍和他汀类药物等广泛使用的药物,有潜力改善疗效、降低放射剂量和降低成本。还讨论了许多其他候选药物。